RedHill Biopharma (RDHL) Competitors $6.33 +0.69 (+12.23%) Closing price 03:58 PM EasternExtended Trading$6.35 +0.02 (+0.32%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends RDHL vs. CMMB, LIAN, CVKD, LSB, CTXR, LGVN, NAII, MTEX, ATHE, and CDIOShould you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include Chemomab Therapeutics (CMMB), LianBio (LIAN), Cadrenal Therapeutics (CVKD), Lakeshore Biopharma (LSB), Citius Pharmaceuticals (CTXR), Longeveron (LGVN), Natural Alternatives International (NAII), Mannatech (MTEX), Alterity Therapeutics (ATHE), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry. RedHill Biopharma vs. Chemomab Therapeutics LianBio Cadrenal Therapeutics Lakeshore Biopharma Citius Pharmaceuticals Longeveron Natural Alternatives International Mannatech Alterity Therapeutics Cardio Diagnostics Chemomab Therapeutics (NASDAQ:CMMB) and RedHill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking. Do institutionals and insiders believe in CMMB or RDHL? 46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of RedHill Biopharma shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 6.8% of RedHill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, CMMB or RDHL? Chemomab Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, RedHill Biopharma has a beta of 3.69, meaning that its share price is 269% more volatile than the S&P 500. Which has preferable earnings & valuation, CMMB or RDHL? RedHill Biopharma has higher revenue and earnings than Chemomab Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$1.00-2.10RedHill Biopharma$6.53M1.24$23.92MN/AN/A Is CMMB or RDHL more profitable? RedHill Biopharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% RedHill Biopharma N/A N/A N/A Does the MarketBeat Community favor CMMB or RDHL? RedHill Biopharma received 409 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.24% of users gave RedHill Biopharma an outperform vote while only 64.29% of users gave Chemomab Therapeutics an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1864.29% Underperform Votes1035.71% RedHill BiopharmaOutperform Votes42767.24% Underperform Votes20832.76% Does the media favor CMMB or RDHL? In the previous week, RedHill Biopharma had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for RedHill Biopharma and 0 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.00 beat RedHill Biopharma's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chemomab Therapeutics Positive RedHill Biopharma Neutral Do analysts recommend CMMB or RDHL? Chemomab Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 257.14%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Chemomab Therapeutics is more favorable than RedHill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50RedHill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRedHill Biopharma beats Chemomab Therapeutics on 8 of the 15 factors compared between the two stocks. Get RedHill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedHill BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.10M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / Sales1.24335.351,284.8380.47Price / Cash0.0122.6336.6032.90Price / Book0.165.084.964.69Net Income$23.92M$154.90M$117.89M$224.57M7 Day Performance14.88%2.59%2.74%3.33%1 Month Performance-2.62%1.52%3.63%5.33%1 Year Performance-98.92%5.49%27.26%22.97% RedHill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedHill Biopharma0.2051 of 5 stars$6.33+12.2%N/A-99.0%$8.10M$6.53M0.00210News CoveragePositive NewsHigh Trading VolumeCMMBChemomab Therapeutics3.7698 of 5 stars$1.98-6.6%$7.50+278.8%+308.3%$28.43MN/A-1.9820Positive NewsLIANLianBioN/A$0.26+1.2%N/A-94.3%$28.43MN/A-0.32110CVKDCadrenal Therapeutics2.4278 of 5 stars$15.58-4.2%$32.00+105.4%N/A$27.78MN/A-2.334Positive NewsLSBLakeshore Biopharma1.2456 of 5 stars$2.97-3.6%N/AN/A$27.64M$672.27M0.00773CTXRCitius Pharmaceuticals2.0906 of 5 stars$3.48-4.1%$54.50+1,466.1%-81.7%$26.89MN/A-0.5820Short Interest ↑LGVNLongeveron3.5002 of 5 stars$1.77-1.4%$8.67+391.0%-82.1%$26.19M$1.89M-0.2823Positive NewsNAIINatural Alternatives International1.0182 of 5 stars$4.20-0.2%N/A-33.2%$26.04M$112.98M-2.92290Analyst ForecastPositive NewsMTEXMannatech0.2554 of 5 stars$13.75-8.2%N/A+33.6%$25.92M$121.55M-16.98250Analyst ForecastGap UpATHEAlterity Therapeutics2.1691 of 5 stars$3.52+5.4%$6.00+70.5%+83.9%$25.71MN/A0.0010Short Interest ↑CDIOCardio Diagnostics2.5256 of 5 stars$0.63-6.2%$2.00+217.7%-76.1%$25.46M$35,688.000.007Gap Down Related Companies and Tools Related Companies Chemomab Therapeutics Competitors LianBio Competitors Cadrenal Therapeutics Competitors Lakeshore Biopharma Competitors Citius Pharmaceuticals Competitors Longeveron Competitors Natural Alternatives International Competitors Mannatech Competitors Alterity Therapeutics Competitors Cardio Diagnostics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RDHL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RedHill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share RedHill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts